-
1 Comment
JCR Pharmaceuticals Co., Ltd is currently in a long term uptrend where the price is trading 17.9% above its 200 day moving average.
From a valuation standpoint, the stock is 77.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 15.8.
JCR Pharmaceuticals Co., Ltd's total revenue rose by 23.9% to $8B since the same quarter in the previous year.
Its net income has increased by 130.7% to $2B since the same quarter in the previous year.
Based on the above factors, JCR Pharmaceuticals Co., Ltd gets an overall score of 4/5.
| Sector | Healthcare |
|---|---|
| Industry | Drug Manufacturers - General |
| ISIN | JP3701000006 |
| Exchange | TSE |
| CurrencyCode | JPY |
| Market Cap | 58B |
|---|---|
| PE Ratio | None |
| Dividend Yield | 4.3% |
| Target Price | 772.8571 |
| Beta | 0.07 |
JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was founded in 1975 and is based in Ashiya, Japan.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 4552.TSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
